Company Overview: Lightlake Therapeutics

Industry News

3 Jun

Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone

Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited (“Adapt”), Lightlake’s partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States...

Read more

22 Apr

Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study

Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited (“Adapt”), Lightlake’s partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone. The pharmacokinetic study compared intranasal naloxone with...

Read more

9 Apr

Initiating Coverage on the Most Compelling Drug Reformulation Story of 2015

One Equity Research is initiating coverage on Lightlake Therapeutics (OTCQB: LLTP) as the most compelling risk-adjusted drug reformulation story of 2015. See our full report for details. The Billion Dollar Healthcare Epidemic The leading cause of drug-related death is opioid overdose, a market opportunity estimated at $1B+ per annum....

Read more

9 Mar

Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing

Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation. Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the March 5th presentation from Dr. Roger Crystal , Chief...

Read more

5 Mar

Lightlake Therapeutics Inc., Licensor Of A Treatment To Reverse Opioid Overdoses, To Webcast Live, At VirtualInvestorConferences.com March 5th

Lightlake invites individual and institutional investors to attend interactive real-time presentation on Lightlake’s progress with its opioid overdose reversal treatment and achievements in other areas. NEW YORK , Feb. 27, 2015 /PRNewswire/ — Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid...

Read more

27 Feb

Lightlake Therapeutics Inc., Licensor Of A Treatment To Reverse Opioid Overdoses, To Webcast Live, At VirtualInvestorConferences.com March 5th

Lightlake invites individual and institutional investors to attend interactive real-time presentation on Lightlake’s progress with its opioid overdose reversal treatment and achievements in other areas. – Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that its Chief...

Read more

17 Feb

Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose

Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake’s partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration (“FDA”).  Under the...

Read more

9 Feb

Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs

Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015. Mr. Agrawal brings over 20 years of experience in medical and public affairs, scientific...

Read more

16 Dec

Lightlake Therapeutics Inc. Announces Licensing Deal With Adapt Pharma Limited Subsidiary

Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has entered into a license agreement with Adapt Pharma Operations Limited (“Adapt”), a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company (“Adapt Pharma”). Pursuant...

Read more

4 Dec

Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)

Lightlake Therapeutics advances collaboration with NIDA for novel intranasal naloxone application to reverse opioid overdose Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address